CLRB (Cellectar Biosciences) LT-Debt-to-Total-Asset: 0.14 (As of Mar. 2026)


CLRB Cellectar Biosciences Inc CLRB
28 GF Score
Price $2.50
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences LT-Debt-to-Total-Asset?

Cellectar Biosciences CLRB +1.20% 28 LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus rates CLRB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cellectar Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.14.

Cellectar Biosciences's long-term debt to total assets ratio increased from Mar. 2025 (0.02) to Mar. 2026 (0.14). It may suggest that Cellectar Biosciences is progressively becoming more dependent on debt to grow their business.

Cellectar Biosciences  (NAS:CLRB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cellectar Biosciences LT-Debt-to-Total-Asset Related Terms

Cellectar Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences LT-Debt-to-Total-Asset Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.03 0.04 0.02 0.02

Cellectar Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.02 0.02 0.14
CLRB
28GF Score
Cellectar Biosciences Inc CLRB
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences LT-Debt-to-Total-Asset Calculation

Cellectar Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.309/14.978
=

Cellectar Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=1.529/11.12
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.14 mean?
Cellectar Biosciences (CLRB) has a LT-Debt-to-Total-Asset of 0.14 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' LT-Debt-to-Total-Asset too high?
Cellectar Biosciences' current LT-Debt-to-Total-Asset is 0.14. Overall, Cellectar Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' LT-Debt-to-Total-Asset compare to PTN and PLUR?
Cellectar Biosciences' LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current LT-Debt-to-Total-Asset of 0.14. The current LT-Debt-to-Total-Asset is 0.14. Cellectar Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
28GF Score

Get the complete analysis for CLRB

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.50
Price